Where your peptides come from, and why it is the first question
Most of the risk in a peptide program sits upstream of the prescription. Here is how to ask a supplier the one question that matters, and what a good answer sounds like.
A prescriber carries the consequences of what they sign. With peptides, most of the exposure is decided before that moment, by where the vial came from.
Two supply stories
- A licensed United States compounding pharmacy prepares the medicine against a patient’s prescription, from a substance it is permitted to use.
- A bulk peptide is imported and sold on, often labelled "research use only", sometimes through a clinic.
Only the first is a supply chain. The second is the pattern that produced a federal indictment of a physician in April 2026, and enforcement there is coordinated across agencies. The label on the vial changes nothing.
The rules moved in 2026, and are still moving
Several well-known peptides were reclassified in 2026, and an advisory committee has recommended adding more to the compounding list. Recommendations are not rules yet, and formal rulemaking runs slowly. A clinic that builds a menu on a headline will be rewriting it.
What this means for a menu
- Keep the list to what a licensed pharmacy will actually prepare today.
- Know which entries are settled and which are pending, and expect the pending ones to change.
- Write down where each one comes from, before a patient asks.
A menu you can defend
Sana Crest keeps the shelf, the sourcing and the record in one place, under your clinic’s name.
This article is general information and is not legal advice. Telehealth and prescribing rules vary by state and change over time. Check with healthcare counsel before acting.
